Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) and Galectin Therapeutics (NASDAQ:GALT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.
Volatility and Risk
Phio Pharmaceuticals has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
Insider & Institutional Ownership
57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Phio Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
| Galectin Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Phio Pharmaceuticals currently has a consensus target price of $14.00, indicating a potential upside of 1,011.11%. Galectin Therapeutics has a consensus target price of $11.00, indicating a potential upside of 292.86%. Given Phio Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Phio Pharmaceuticals is more favorable than Galectin Therapeutics.
Valuation and Earnings
This table compares Phio Pharmaceuticals and Galectin Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Phio Pharmaceuticals | N/A | N/A | -$8.70 million | ($1.45) | -0.87 |
| Galectin Therapeutics | N/A | N/A | -$47.05 million | ($0.59) | -4.75 |
Galectin Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Phio Pharmaceuticals and Galectin Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Phio Pharmaceuticals | N/A | -66.59% | -60.26% |
| Galectin Therapeutics | N/A | N/A | -268.71% |
Summary
Phio Pharmaceuticals beats Galectin Therapeutics on 5 of the 9 factors compared between the two stocks.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
About Galectin Therapeutics
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
